产品目录
| 编号 | 化学名称 | Cas号 | 纯度 | 化学结构 |
|---|---|---|---|---|
| 2071527 | GSK8612 | 2361659-62-1 | 98% Min. |  |
| GSK8612 is a potent and highly selective TBK1 inhibitor. GSK8612 inhibited recombinan | ||||
| 2071522 | GSK547 | 98% Min. |  | |
| GSK547 is a highly selective and potent inhibitor of RIP1 kinase that targets RIP1 in | ||||
| 2071511 | GSK1016790A | 942206-85-1 | 98% Min. |  |
| GSK1016790A, also known as GSK101, is a TRPV4 agonist that elicits calcium influx in | ||||
| 2071509 | GNE-131 | 1629063-81-5 | 98% Min. |  |
| GNE-131 is a Potent and Selective hNaV1.7 Inhibitor (Na V1.7 IC50 = 3 nM) for the Tre | ||||
| 2061310 | GW284543 | 790186-68-4 | 98% Min. |  |
| GW284543, also known as UNC10225170;, is a potent and selective MEK5 inhibitor with t | ||||
| 206103 | G-1 | 881639-98-1 | 98% Min. |  |
| G-1 is a selective agonist for GPER. It acts by blocking tubulin polymerization. | ||||
| 203401 | Glumetinib | 1642581-63-2 | 98% Min. |  |
| Glumetinib, also known as SCC244, is a novel, potent and highly selective inhibitor o | ||||
| 111892 | GNE-2861 | 1394121-05-1 | 98% Min. |  |
| GNE-2861 is a potent and exquisitely kinase-selective Group II PAK inhibitor (PAK4 Ki | ||||
| 193293 | GSK-199 | 1549811-53-1 | >98% |  |
| GSK199是一种选择性的PAD4抑制剂，在不含钙的情况下，其半峰抑制 | ||||
| 193221 | GS-626510 | 1637770-13-8 | >98% |  |
| GS-626510是一种有效的BET家族溴域抑制剂。它的作用是针对BRD2/3/4和 | ||||
| 193194 | GSK2837808A | 1445879-21-9 | >98% |  |
| GSK2837808A是一种高效、选择性的乳酸脱氢酶A(LDHA)抑制剂(LDHA和LDHB的 | ||||
| 193185 | GSK-963 | 2049868-46-2 | >98% |  |
| GSK-963，也被称为GSK'963或GSK963，是一种有效的和选择性的RIP1激 | ||||
| 192284 | GNE-9605 | 1536200-31-3 | >98% |  |
| GNE-9605是一种高效、选择性强、脑内渗透的氨基吡唑亮氨酸富集重 | ||||
| 192281 | GSK3004774 | 2138814-32-9 | >98% |  |
| GSK3004774是一种有效的、不可吸收的CaSR激动剂，人、小鼠和大鼠Ca | ||||
| 192251 | GW-3965盐酸盐 | 405911-17-3 | >98% |  |
| GW-3965是一种肝脏X受体激动剂。GW3965抑制小鼠肥大细胞产生促炎细 | ||||
| 192224 | GSK2334470 | 1227911-45-6 | >98% |  |
| GSK2334470是一种有效的3-磷酸肌苷依赖性蛋白激酶(PDK1)抑制剂(IC50 ~ | ||||
| 192201 | GSK269962盐酸盐 | 2095432-71-4 | >98% |  |
| GSK269962是一种选择性ROCK抑制剂，对ROCK-I和ROCK- II的IC50值分别为1.6 | ||||
| 192194 | GW-803430 | 515141-51-2 | >98% |  |
| GW-803430是一种强效、口服活性和选择性黑色素聚集激素受体1 (MCH1 | ||||
| 192181 | GNE-477 | 1032754-81-6 | >98% |  |
| GNE-477是一种有效的双PI3K/mTOR抑制剂。 | ||||
| 191255 | GSKJ1 | 1373422-53-7 | >98% |  |
| GSKJ1是一种具有选择性和有效的组蛋白脱甲基酶抑制剂(GSK-J1)有重 | ||||
| 191144 | GSK2643943A | // | >98% |  |
| GSK2643943A是一种有效的USP20抑制剂，IC50值为160 nM。 | ||||
| 19185 | GSK-2807 | 2245255-65-4 | >98% |  |
| GSK-2807是一种有效且具有选择性的SMYD3的SAM-竞争性抑制剂。 | ||||
| 1812291 | GNE-6640 | 2009273-67-8 | >98% |  |
| GNE-6640是一种新型选择性USP7抑制剂，可诱导肿瘤细胞死亡。GNE-664 | ||||
| 1812102 | GSK1940029 | 1150701-66-8 | >98% |  |
| GSK1940029，又称SCD抑制剂1，是一种SCD抑制剂。GSK1940029能够潜在的局 | ||||
| 181241 | GSK2814338 | 1420367-28-7 | >98% |  |
| GSK2814338，也称为Lp-PLA2 -IN-1，是一种Lp-PLA2抑制剂。 | ||||
| 1811301 | GDC-0927 | 1642297-01-5 | >98% |  |
| GDC-0927, 也称为SRN-927，是下一代口服SERD，其作为一类SERD分子的潜 | ||||
| 1811266 | GSK-5959 | 901245-65-6 | >98% |  |
| GSK-5959是一种有效的选择性BRPF1溴域抑制剂(IC50 = 80 nM)。 | ||||
| 1811263 | GW-870086 | 827319-43-7 | >98% |  |
| GW-870086是一种糖皮质激素受体激动剂，有望用于哮喘和特应性皮炎 | ||||
| 1811233 | GSK9311 | 1923851-49-3 | >98% |  |
| GSK9311是BRPF溴域高效高选择性抑制剂(BRPDF1 pIC50 = 6.0;BRPDF2 pIC50 = 4.3 | ||||
| 1811231 | GW1100 | 306974-70-9 | >98% |  |
| GW1100是一种具有选择性的GPR40拮抗剂。 | ||||